Pharma and Biotech Briefing: M&As, IPOs, and More to Expect in 2H22

Against the ongoing backdrop of geopolitical uncertainty and COVID, the pharma and biotech industries continue to be challenged by growing market volatility and a tougher financing environment compared to previous years.

With the start of 2022 bringing stricter FDA approval processes, a slowdown of biotech investing for the first time in 3 years, and a significant amount of capital allocated for M&A, what key trends and themes should we expect to emerge in the second half of 2022?

• Key themes impacting pharma and biotech and the long- and short-term outlook
• Shifts in M&A interest over time, and what’s most attractive today
• Trends in tech, drug advancements, and therapeutics, as well as recent milestones driving investor sentiment

SPEAKERS:

• Geoff Meacham - Managing Director, Americas Equity Research, Biotech and Pharma, Bank of America
• Tazeen Ahmad - Managing Director, US Equity Research, Biotech, Bank of America